Show simple item record

dc.contributor.authorBatchelor, T
dc.contributor.authorMulholland, P
dc.contributor.authorNeyns, B
dc.contributor.authorNabors, L
dc.contributor.authorCampone, M
dc.contributor.authorWick, A
dc.contributor.authorMason, W
dc.contributor.authorMikkelsen, T
dc.contributor.authorPhuphanich, S
dc.contributor.authorAshby, L
dc.contributor.authorDegroot, J
dc.contributor.authorGattamaneni, Rao
dc.contributor.authorCher, L
dc.contributor.authorRosenthal, M
dc.contributor.authorPayer, F
dc.contributor.authorJürgensmeier, J
dc.contributor.authorJain, R
dc.contributor.authorSorensen, A
dc.contributor.authorXu, J
dc.contributor.authorLiu, Q
dc.contributor.authorvan den Bent, M
dc.date.accessioned2013-08-30T13:34:36Z
dc.date.available2013-08-30T13:34:36Z
dc.date.issued2013-08-12
dc.identifier.citationPhase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. 2013: J Clin Oncolen_GB
dc.identifier.issn1527-7755
dc.identifier.pmid23940216
dc.identifier.doi10.1200/JCO.2012.47.2464
dc.identifier.urihttp://hdl.handle.net/10541/300435
dc.description.abstractA randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.titlePhase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.en
dc.typeArticleen
dc.contributor.departmentTracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.en_GB
dc.identifier.journalJournal of Clinical Oncologyen_GB
html.description.abstractA randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.


This item appears in the following Collection(s)

Show simple item record